Novartis Blasts Attempt To Revive Pay-For-Delay Suit
Novartis Pharmaceuticals Corp. on Friday urged the First Circuit to nix allegations it used a sham litigation to extend its monopoly over the leukemia drug Gleevec, saying a lower court correctly...To view the full article, register now.
Already a subscriber? Click here to view full article